• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Neovasc Inc.

    4/11/23 8:47:28 AM ET
    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $NVCN alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-36458
    Issuer: NEOVASC INC
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: Suite 2135, 13700 Mayfield Place
    Richmond BRITISH COLUMBIA, CANADA V6V 2E4
    Telephone number: 6,042,704,344
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common shares
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-04-11 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVCN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink resumed coverage on Neovasc with a new price target

      SVB Leerink resumed coverage of Neovasc with a rating of Buy and set a new price target of $2.00

      3/14/21 8:09:11 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o

      3/6/23 6:00:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh

      3/6/23 5:37:44 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Neovasc Inc. (Amendment)

      SC 13G/A - NEOVASC INC (0001399708) (Subject)

      2/14/22 3:25:50 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed

      SC 13D - NEOVASC INC (0001399708) (Subject)

      2/25/21 3:14:38 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed

      SC 13G - NEOVASC INC (0001399708) (Subject)

      2/19/21 4:24:07 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Financials

    Live finance-specific insights

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

      VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") ((NASDAQ, TSX:NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company re

      11/10/22 4:05:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc to Report Third Quarter Financial Results on November 10, 2022

      VANCOUVER and MINNEAPOLIS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022. Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc we

      10/27/22 9:00:00 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Neovasc Inc.

      EFFECT - NEOVASC INC (0001399708) (Filer)

      8/3/23 12:15:07 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 15F-12B filed by Neovasc Inc.

      15F-12B - NEOVASC INC (0001399708) (Filer)

      4/24/23 4:15:05 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Neovasc Inc.

      6-K - NEOVASC INC (0001399708) (Filer)

      4/12/23 1:10:18 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care